Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis

Haguet, Hélène; Douxfils, Jonathan; Mullier, François; Chatelain, C; Graux, Carlos; Dogné, Jean-Michel

doi:10.1080/14740338.2017.1261824

Public

Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis

Published in Expert Opinion on Drug Safety • Nov 17, 2016

Authors:

Hélène Haguet

Jonathan Douxfils

François Mullier

Abstract

Background: A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic myeloid leukemia compared with imatinib. This ...

Subject

Medicine

Myeloid leukemia

Tyrosine kinase

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!